Study backs rapid test for "super bugs":
This article was originally published in Clinica
Executive Summary
Canadian firm ID Biomedical will file in February for FDA-clearance to market its rapid test for methicillin-resistant Staphylococcus aureus (MRSA) after receiving promising preliminary results in US clinical trials. The test for the potentially fatal so-called "superbugs", which are becoming increasingly prevalent in hospitals, was shown to have an accuracy of 100% in an analysis of 308 samples. The Velogene Rapid MRSA test, which is based on the Vancouver, British Columbia company's Cycling Probe Technology, detects the mecA gene responsible for antibiotic resistance.